Heterogeneity of hepatocellular carcinoma that responds differently to combination therapy with TACE and Sorafenib as determined by digital spatial gene expression profiling.

Chenhao XuRenyi SuZhengyang LuYisu SongXiaobing ZhangWenzhi ShuZhe YangRunzhou ZhuangXiao XuXuyong Wei

Published in: Genes & genomics (2024)

TAM infiltration may play a key role. Meanwhile, the introduction of immunotherapy in patients resistant to combination therapy may lead to positive results.

Keyphrases

combination therapy
end stage renal disease
genome wide
ejection fraction
chronic kidney disease
newly diagnosed
peritoneal dialysis
prognostic factors
single cell
genome wide identification
gene expression
patient reported outcomes
copy number
transcription factor
patient reported